Kangti Pte Ltd ("the Company") was incorporated in the Republic of Singapore in 2012 and commenced its R&D operation in 2015.

The Company has developed technologies that will spearhead breakthroughs in the discovery of human therapeutic antibodies capable of modulating in vivo activities of the G-Protein Coupled Receptors (GPCRs).

GPCRs are one of the most intensively studied and explored drug targets. They are involved in a wide variety of human diseases including hypertension, allergy, depression, and many other neurodegenerative, metabolic, and infectious diseases. Currently, the sales of GPCR targeting drugs represent about 30% of the global drug market of approximately $1,200 billion and are expected to continue to increase in the next decade.  However, the GPCR-targeting antibody drugs have been eminently lacking. So far, out of 82 antibody drugs approved by FDA, only 2 are targeted at GPCRs. The difficulty in generating functional antibodies against GPCRs lies mainly in the inherent structural properties of these proteins.